Evidence map›Paper›PMID 36574046›Full record

ArticleJournal of cancer research and clinical oncology2023

Establishing a metastasis-related diagnosis and prognosis model for lung adenocarcinoma through CRISPR library and TCGA database.

Fanggui Shao, Liqun Ling, Changhong Li, Xiaolu Huang, Yincai Ye, Meijuan Zhang, Kate Huang, Jingye Pan, Jie Chen, Yumin Wang

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Fanggui Shao *Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Liqun Ling *Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Changhong Li *Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xiaolu HuangDepartment of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yincai YeDepartment of Blood Transfusion, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Meijuan ZhangDepartment of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Kate HuangDepartment of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jingye PanKey Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang Provincial, Wenzhou, China. wmupanjingye@126.com.
Jie ChenDepartment of ICU, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. chenjie991300@163.com.
Yumin WangDepartment of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. wym0577@163.com.ORCID http://orcid.org/0000-0001-8243-3659
Wenzhou Medical University · CN

Funding

the Fundamental Scientific Research Fees of Wenzhou Medical University KYYW2021026the Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province 2022E10022the National Natural Science Foundation of China 81672088Wenzhou Municipal Science and Technology Bureau of China Y20220127, Y20190461Zhejiang Provincial Natural Science Foundation of China LQ22H200003, LY19H200002Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology JBZX-202003
6 · The paper itself

Abstract

purposeExisting biomarkers for diagnosing and predicting metastasis of lung adenocarcinoma (LUAD) may not meet the demands of clinical practice. Risk prediction models with multiple markers may provide better prognostic factors for accurate diagnosis and prediction of metastatic LUAD.

methodsAn animal model of LUAD metastasis was constructed using CRISPR technology, and genes related to LUAD metastasis were screened by mRNA sequencing of normal and metastatic tissues. The immune characteristics of different subtypes were analyzed, and differentially expressed genes were subjected to survival and Cox regression analyses to identify the specific genes involved in metastasis for constructing a prediction model. The biological function of RFLNA was verified by analyzing CCK-8, migration, invasion, and apoptosis in LUAD cell lines.

resultsWe identified 108 differentially expressed genes related to metastasis and classified LUAD samples into two subtypes according to gene expression. Subsequently, a prediction model composed of eight metastasis-related genes (RHOBTB2, KIAA1524, CENPW, DEPDC1, RFLNA, COL7A1, MMP12, and HOXB9) was constructed. The areas under the curves of the logistic regression and neural network were 0.946 and 0.856, respectively. The model effectively classified patients into low- and high-risk groups. The low-risk group had a better prognosis in both the training and test cohorts, indicating that the prediction model had good diagnostic and predictive power. Upregulation of RFLNA successfully promoted cell proliferation, migration, invasion, and attenuated apoptosis, suggesting that RFLNA plays a role in promoting LUAD development and metastasis.

conclusionThe model has important diagnostic and prognostic value for metastatic LUAD and may be useful in clinical applications.

Indexed as

AdenocarcinomaAdenocarcinoma of LungLung NeoplasmsAnimalsClustered Regularly Interspaced Short Palindromic RepeatsPrognosisDiagnosisLung adenocarcinomaMetastasisPrognosisRFLNA

Identifiers

PMID36574046
PMCPMC11797453
OpenAlexW4312212251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.